Is the time in therapeutic range using the ratio of tests equivalent to the Rosendaal method?

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 8, 2015, Pages 972-976

  Caldeira, Daniel ^a,b,c   Cruz, Inês ^a   Morgado, Gonçalo ^a   Stuart, Bruno ^a   Gomes, Ana Catarina ^a   Martins, Cristina ^a   João, Isabel ^a   Pereira, Hélder ^a  

^a HOSPITAL GARCIA DE ORTA   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Anticoagulation quality; Rosendaal method; Tests ratio; Time in therapeutic range; Vitamin K antagonist; Warfarin

Indexed keywords

ANTIVITAMIN K; ANTICOAGULANT AGENT; VITAMIN K GROUP;

AGED; ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHARMACOLOGICAL PARAMETERS; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ROSENDAAL METHOD; SENSITIVITY AND SPECIFICITY; TIME IN THERAPEUTIC RANGE; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; COMPLICATION; DIABETES MELLITUS; DRUG EFFECTS; HEART FAILURE; HYPERTENSION; OUTPATIENT; STANDARDS; STATISTICAL MODEL; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DIABETES MELLITUS; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LINEAR MODELS; MALE; OUTPATIENTS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; STROKE; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 84947053351     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000312     Document Type: Article

References (16)

1. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146:857-867.
2. Menzin J, Boulanger L, Hauch O, Friedman M, Marple CB, Wygant G, et al. Quality of anticoagulation control and costs of monitoring warfarin therapy among patients with atrial fibrillation in clinic settings: a multisite managed-care study. Ann Pharmacother 2005; 39:446-451.
3. Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69:236-239.
4. Hutten BA, Prins MH, Redekop WK, Tijssen JG, Heisterkamp SH, Büller HR. Comparison of three methods to assess therapeutic quality control of treatment with vitamin K antagonists. Thromb Haemost 1999; 82:1260-1263.
5. Carrier M, Kimpton M, Wells PS, Langlois N, Kherani S, Le Gal G. A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants. Blood Coagul Fibrinolysis 2014; 25:812-815.
6. Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, et al. Dabigatran and warfarin in vitamin K antagonist-naive and - experienced cohorts with atrial fibrillation. Circulation 2010; 122:2246-2253.
7. Caldeira D, Cruz I, Morgado G, Stuart B, Gomes C, Martins C, et al. Evaluation of time in therapeutic range in anticoagulated patients: a single-center, retrospective, observational study. BMC Res Notes 2014; 7:891.
8. Wissler C. The Spearman correlation formula. Science 1905; 22:309-311.
9. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1:307-310.
10. Passing H, Bablok. A new biometrical procedure for testing the equality of measurements from two different analytical methods. Application of linear regression procedures for method comparison studies in clinical chemistry, Part I. J Clin Chem Clin Biochem 1983; 21:709-720.
11. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, Albers GW. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167:239-245.
12. Rose AJ, Ozonoff A, Henault LE, Hylek EM. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost 2008; 6:1647-1654.
13. Vijenthira A, Le Gal G, Castellucci LA, Carrier M. Defining time in therapeutic range for busy clinicians: frequency of dose changes is a good surrogate marker to identify patients with suboptimal anticoagulation with warfarin. Thromb Res 2014; 134:584-586.
14. Mearns ES, White CM, Kohn CG, Hawthorne J, Song JS, Meng J, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J 2014; 12:14.
15. Reiffel JA. Novel oral anticoagulants. Am J Med 2014; 127:e16-e17.
16. Caldeira D, Barra M, David C, Costa J, Ferreira JJ, Pinto FJ. The prevalence of oral anticoagulation in patients with atrial fibrillation in Portugal: systematic review and meta-analysis of observational studies. Rev Port Cardiol 2014; 33:555-560.